

Publications for Alan Coates

2019

Ackland, S., GebSKI, V., Zdenkowski, N., Wilson, A., Green, M., Tees, S., Dhillon, H., van Hazel, G., Levi, J., Simes, R., Coates, A., et al (2019). Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311. *Breast Cancer Research and Treatment*, 176(2), 357-365. [More Information]

Dellapasqua, S., Gray, K., Munzone, E., Rubino, D., Gianni, L., Johansson, H., Viale, G., Ribl, K., Bernhard, J., Kammler, R., Coates, A., et al (2019). Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. *Journal of Clinical Oncology*, 37(5), 386-395. [More Information]

Ribl, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., Neven, P., Di Lauro, V., Gomez, H., Coates, A., et al (2019). Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. *British Journal of Cancer*, 120(10), 959-967. [More Information]

2018

Ruhstaller, T., Giobbie-Hurder, A., Colleoni, M., Jensen, M., Ejlertsen, B., de Azambuja, E., Neven, P., Lang, I., Jakobsen, E., Gladiéff, L., Coates, A., et al (2018). Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. *Journal of Clinical Oncology*, 37(2), 105-114. [More Information]

Ribl, K., Coates, A., Blacher, L., Regan, M., Gelber, R., Bernhard, J. (2018). Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al. *Quality of Life Research*, 27(1), 149-152. [More Information]

Galimberti, V., Cole, B., Viale, G., Veronesi, P., Vicini, E., Intra, M., Mazzarol, G., Massarut, S., Zgajnar, J., Coates, A., et al (2018). Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *The Lancet Oncology*, 19(10), 1385-1393. [More Information]

Wapnir, I., Price, K., Anderson, S., Robidoux, A., Martini, M., Nortier, J., Paterson, A., Rimawi, M., Lang, I., Baena-Canada, J., Coates, A., et al (2018). Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. *Journal of Clinical Oncology*, 36(11), 1073-1079. [More Information]

Colleoni, M., Luo, W., Karlsson, P., Chirgwin, J., Aebi, S.,

Jerusalem, G., Neven, P., Hitre, E., Graas, M., Coates, A., et al (2018). Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *The Lancet Oncology*, 19(1), 127-138. [More Information]

Munzone, E., Gray, K., Fumagalli, C., Guerini-Rocco, E., Lang, I., Ruhstaller, T., Gianni, L., Kammler, R., Viale, G., Di Leo, A., Coates, A., et al (2018). Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. *Breast Cancer Research and Treatment*, 170(2), 351-360. [More Information]

Lee, C., Hudson, M., Simes, R., Ribl, K., Bernhard, J., Coates, A. (2018). When do patient reported quality of life indicators become prognostic in breast cancer? *Health and Quality of Life Outcomes*, 16(1), 13. [More Information]

2017

Borgquist, S., Giobbie-Hurder, A., Ahern, T., Garber, J., Colleoni, M., Lang, I., Debled, M., Ejlertsen, B., von Moos, R., Coates, A., et al (2017). Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study. *Journal of Clinical Oncology*, 35(11), 1179-1188. [More Information]

Regan, M., Walley, B., Francis, P., Fleming, G., Lang, I., Gomez, H., Colleoni, M., Tondini, C., Pinotti, G., Salim, M., Coates, A., et al (2017). Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFT. *Annals of Oncology*, 28(9), 2225-2232. [More Information]

Morden, J., Alvarez, I., Bertelli, G., Coates, A., Coleman, R., Fallowfield, L., Jassem, J., Jones, S., Kilburn, L., Li, P., et al (2017). Long-term follow-up of The Intergroup Exemestane Study. *Journal of Clinical Oncology*, 35(22), 2507-2514. [More Information]

Wapnir, I., Gelber, S., Anderson, S., Mamounas, E., Robidoux, A., Martin, M., Nortier, J., Geyer, C., Paterson, A., Coates, A., et al (2017). Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. *Annals of Surgical Oncology*, 24(2), 398-406. [More Information]

Saha, P., Regan, M., Pagni, O., Francis, P., Walley, B., Ribl, K., Bernhard, J., Luo, W., Gomez, H., Coates, A., et al (2017). Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials. *Journal of Clinical Oncology*, 35(27), 3113-3122. [More Information]

2016

Regan, M., Francis, P., Pagani, O., Fleming, G., Walley, B., Viale, G., Colleoni, M., Lang, I., Gomez, H., Tondini, C., Coates, A., et al (2016). Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, Human epidermal growth factor receptor 2-Negative early breast cancer: TEXT and SOFT Trials. *Journal of Clinical Oncology*, 34(19), 2221-2230. [More Information]

Phillips, K., Regan, M., Ribí, K., Francis, P., Puglisi, F., Bellet, M., Spazzapan, S., Karlsson, P., Budman, D., Zaman, K., Coates, A., Boyle, F., et al (2016). Adjuvant ovarian function suppression and cognitive function in women with breast cancer. *British Journal of Cancer*, 114(9), 956-964. [More Information]

Ribi, K., Luo, W., Bernhard, J., Francis, P., Burstein, H., Ciruelos, E., Bellet, M., Pavesi, L., Lluch, A., Coates, A., et al (2016). Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial. *Journal of Clinical Oncology*, 34(14), 1601-1610. [More Information]

Colleoni, M., Sun, Z., Price, K., Karlsson, P., Forbes, J., Thurlimann, B., Gianni, L., Castiglione-Gertsch, M., Gelber, R., Coates, A., et al (2016). Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V. *Journal of Clinical Oncology*, 34(9), 927-935. [More Information]

Johansson, H., Gray, K., Pagani, O., Regan, M., Viale, G., Aristarco, V., Macis, D., Puccio, A., Roux, S., Coates, A., et al (2016). Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. *Breast Cancer Research*, 18(1), 1-12. [More Information]

Colleoni, M., Gray, K., Gelber, S., Lang, I., Thurlimann, B., Gianni, L., Abdi, E., Gomez, H., Linderholm, B., Coates, A., et al (2016). Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00. *Journal of Clinical Oncology*, 34(28), 3400-3408. [More Information]

Zdenkowski, N., Forbes, J., Boyle, F., Kannourakis, G., Gill, P., Bayliss, E., Saunders, C., Della-Fiorentina, S., Kling, N., Coates, A., GebSKI, V., Davies, L., et al (2016). Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): An open-label randomised, controlled trial. *Annals of Oncology*, 27(5), 806-812. [More Information]

Karlsson, P., Cole, B., Price, K., Gelber, R., Coates, A., Goldhirsch, A., Castiglione-Gertsch, M., Colleoni, M., Gruber, G. (2016). Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII. *International Journal of Radiation: Oncology - Biology - Physics*, 96(2), 273-279. [More Information]

Chirgwin, J., Giobbie-Hurder, A., Coates, A., Price, K., Ejlersen, B., Debled, M., Gelber, R., Goldhirsch, A., Smith, I., Rabaglio, M., et al (2016). Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence. *Journal of Clinical Oncology*, 34(21), 2452-2459. [More Information]

2015

Francis, P., Regan, M., Fleming, G., Lang, I., Ciruelos, E., Bellet, M., Bonnefoi, H., Climent, M., Da Prada, G., Burstein, H., Coates, A., et al (2015). Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. *New England Journal of Medicine*, 372(5), 436-446. [More Information]

Dowsett, M., Forbes, J., Bradley, R., Ingle, J., Aihara, T., Bliss, J., Boccardo, F., Coates, A., Coombes, R., Cuzick, J., et al (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *The Lancet*, 386(10001), 1341-1352. [More Information]

Leyland-Jones, B., Gray, K., Abramovitz, M., Bouzyk, M., Young, B., Long, B., Kammler, R., Dell'Orto, P., Biassi, M., Thurlimann, B., Coates, A., et al (2015). CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. *Breast Cancer Research and Treatment*, 151(2), 373-384. [More Information]

Leyland-Jones, B., Gray, K., Abramovitz, M., Bouzyk, M., Young, B., Long, B., Kammler, R., Dell'Orto, P., Biassi, M., Thurlimann, B., Coates, A., et al (2015). ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. *Breast Cancer Research and Treatment*, 154(3), 543-555. [More Information]

Munzone, E., Giobbie-Hurder, A., Gusterson, B., Mallon, E., Viale, G., Thurlimann, B., Ejlersen, B., MacGrogan, G., Bibeau, F., Lelkaitis, G., Coates, A., et al (2015). Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. *Annals of Oncology*, 26(12), 2442-2449. [More Information]

Bernhard, J., Luo, W., Ribí, K., Colleoni, M., Burstein, H., Tondini, C., Pinotti, G., Spazzapan, S., Ruhstaller, T., Puglisi, F., Coates, A., et al (2015). Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. *The Lancet Oncology*, 16(7), 848-858. [More Information]

Regan, M., Pagani, O., Francis, P., Fleming, G., Walley, B., Kammler, R., Dell'Orto, P., Russo, L., Szoke, J., Doimi, F., Coates, A., et al (2015). Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. *Breast Cancer Research and Treatment*,

154(2), 275-286. [More Information]

Filho, O., Giobbie-Hurder, A., Mallon, E., Gusterson, B., Viale, G., Winer, E., Thurlimann, B., Gelber, R., Colleoni, M., Ejlertsen, B., Coates, A., et al (2015). Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. *Journal of Clinical Oncology*, 33(25), 2772-2779. [More Information]

Coates, A., Winer, E., Goldhirsch, A., Gelber, R., Gnant, M., Piccart-Gebhart, M., Thurlimann, B., Senn, H. (2015). Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Annals of Oncology*, 26(8), 1533-1546. [More Information]

2014

Pagani, O., Regan, M., Walley, B., Fleming, G., Colleoni, M., Lang, I., Gomez, H., Tondini, C., Burstein, H., Perez, E., Coates, A., et al (2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *New England Journal of Medicine*, 371(2), 107-118. [More Information]

DeCensi, A., Sun, Z., Guerrieri-Gonzaga, A., Thurlimann, B., McIntosh, C., Tondini, C., Monnier, A., Campone, M., Debled, M., SchÅ¶nenberger, A., Coates, A., et al (2014). Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. *Breast Cancer Research and Treatment*, 144(2), 321-329. [More Information]

Aebi, S., Gelber, S., Anderson, S., Lang, I., Robidoux, A., Martin, M., Nortier, J., Paterson, A., Rimawi, M., Canada, J., Coates, A., et al (2014). Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. *The Lancet Oncology*, 15(2), 156-163. [More Information]

Goldhirsch, A., Coates, A. (2014). Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer. *Annals of Oncology*, 25(3), 755-755. [More Information]

Huober, J., Cole, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J., Neven, P., Lang, I., Coates, A., et al (2014). Symptoms of endocrine treatment and outcome in the BIG 1-98 study. *Breast Cancer Research and Treatment*, 143(1), 159-169. [More Information]

2013

Crivellari, D., Gray, K., Dellapasqua, S., Puglisi, F., Ribbi, K., Price, K., Lang, I., Gianni, L., Spazzapan, S., Pinotti, G., Coates, A., et al (2013). Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial. *Breast*, 22(2), 130-137. [More Information]

Regan, M., Pagani, O., Fleming, G., Walley, B., Price, K.,

Rabaglio, M., Maibach, R., Ruepp, B., Coates, A., Goldhirsch, A., et al (2013). Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. *The Breast*, 22(6), 1094-1100. [More Information]

Galimberti, V., Cole, B., Zurrada, S., Viale, G., Luini, A., Veronesi, P., Baratella, P., Chifu, C., Sargenti, M., Intra, M., Coates, A., et al (2013). Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. *The Lancet Oncology*, 14(4), 297-305. [More Information]

Metzger-Filho, O., Sun, Z., Viale, G., Price, K., Crivellari, D., Snyder, R., Gelber, R., Castiglione-Gertsch, M., Coates, A., Goldhirsch, A., et al (2013). Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node-Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX. *Journal of Clinical Oncology*, 31(25), 3083-3090. [More Information]

Goldhirsch, A., Winer, E., Coates, A., Gelber, R., Piccart-Gebhart, M., Thurlimann, B., Senn, H. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology*, 24(9), 2206-2223. [More Information]

Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. *SpringerPlus*, 2(391), 1-10. [More Information]

2012

Regan, M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell'Orto, P., Biasi, M., Thurlimann, B., Lyng, M., Coates, A., et al (2012). CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. *Journal of the National Cancer Institute*, 104(6), 441-451. [More Information]

Bliss, J., Kilburn, L., Coleman, R., Forbes, J., Coates, A., Jones, S., Jassem, J., Delozier, T., Andersen, J., Paridaens, R., et al (2012). Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study. *Journal of Clinical Oncology*, 30(7), 709-717. [More Information]

Coates, A., Colleoni, M., Goldhirsch, A. (2012). Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer? *Journal of Clinical Oncology*, 30(12), 1260-1263. [More Information]

Ewertz, M., Gray, K., Regan, M., Ejlertsen, B., Price, K., Thurlimann, B., Bonnefoi, H., Forbes, J., Paridaens, R., Rabaglio, M., Coates, A., et al (2012). Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With

Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. *Journal of Clinical Oncology*, 30(32), 3967-3975. [More Information]

Huober, J., Gelber, S., Goldhirsch, A., Coates, A., Viale, G., Ohlschlegel, C., Price, K., Gelber, R., Regan, M., Thurlimann, B. (2012). Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. *Annals of Oncology*, 23(11), 2843-2851. [More Information]

Coates, A., Millar, E., O'Toole, S., Molloy, T., Viale, G., Goldhirsch, A., Regan, M., Gelber, R., Sun, Z., Castiglione-Gertsch, M., et al (2012). Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. *Breast Cancer Research*, 14(6), 1-12. [More Information]

Ribi, K., Aldridge, J., Phillips, K., Thompson, A., Harvey, V., Thurlimann, B., Cardoso, F., Pagani, O., Coates, A., Goldhirsch, A., et al (2012). Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. *British Journal of Cancer*, 106(10), 1618-1625. [More Information]

Chirgwin, J., Sun, Z., Smith, I., Price, K., Thurlimann, B., Ejlersen, B., Bonnefoi, H., Regan, M., Goldhirsch, A., Coates, A. (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. *Breast Cancer Research and Treatment*, 131(1), 295-306. [More Information]

2011

Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., GebSKI, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. *Breast Cancer Research and Treatment*, 129(2), 467-476. [More Information]

Colleoni, M., Giobbie-Hurder, A., Regan, M., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J., Paridaens, R., Lang, I., Smith, I., Coates, A., et al (2011). Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. *Journal of Clinical Oncology*, 29(9), 1117-1124. [More Information]

Regan, M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlersen, B., Mauriac, L., Forbes, J., Smith, I., Lang, I., Wardley, A., Coates, A., et al (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. *The Lancet Oncology*, 12(12), 1101-1108. [More Information]

Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., GebSKI, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. *Journal of Clinical Oncology*, 29(34),

4498-4504. [More Information]

Phillips, K., Aldridge, J., Ribi, K., Sun, Z., Thompson, A., Harvey, V., Thurlimann, B., Cardoso, F., Pagani, O., Coates, A., et al (2011). Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. *Breast Cancer Research and Treatment*, 126(1), 221-226. [More Information]

Aebi, S., Sun, Z., Braun, D., Price, K., Castiglione-Gertsch, M., Rabaglio, M., Gelber, R., Crivellari, D., Lindtner, J., Snyder, R., Coates, A., et al (2011). Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. *Annals of Oncology*, 22(9), 1981-1987. [More Information]

Karlsson, P., Sun, Z., Braun, D., Price, K., Castiglione-Gertsch, M., Rabaglio, M., Gelber, R., Crivellari, D., Collins, J., Murray, E., Coates, A., et al (2011). Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. *Annals of Oncology*, 22(10), 2216-2226. [More Information]

Goldhirsch, A., Wood, W., Coates, A., Gelber, R., Thurlimann, B., Senn, H. (2011). Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Annals of Oncology*, 22(8), 1736-1747. [More Information]

Viale, G., Regan, M., Dell'Orto, P., Mastropasqua, M., Maiorano, E., Rasmussen, B., MacGrogan, G., Forbes, J., Paridaens, R., Colleoni, M., Coates, A., et al (2011). Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. *Annals of Oncology*, 22(10), 2201-2207. [More Information]

2010

Paridaens, R., Gelber, S., Cole, B., Gelber, R., Thurlimann, B., Price, K., Holmberg, S., Crivellari, D., Coates, A., Goldhirsch, A. (2010). Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. *Breast Cancer Research and Treatment*, 123(1), 303-310. [More Information]

Viale, G., Giobbie-Hurder, A., Gusterson, B., Maiorano, E., Mastropasqua, M., Sonzogni, A., Mallon, E., Colleoni, M., Castiglione-Gertsch, M., et al, Coates, A. (2010). Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. *Annals of Oncology*, 21(2), 245-254. [More Information]

Castellano, I., Allin, E., Accortanzo, V., Vandone, A., Chiusa,

L., Arisio, R., Durando, A., Donadio, M., Bussolati, G., Coates, A., et al (2010). Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. *Breast Cancer Research and Treatment*, 124(3), 607-617. [More Information]

Colleoni, M., Cole, B., Viale, G., Regan, M., Price, K., Maiorano, E., Mastropasqua, M., Crivellari, D., Gelber, R., Goldhirsch, A., Coates, A., et al (2010). Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. *Journal of Clinical Oncology*, 28(18), 2966-2973. [More Information]

Phillips, K., Ribi, K., Sun, Z., Stephens, A., Thompson, A., Harvey, V., Thurlimann, B., Cardoso, F., Pagani, O., Coates, A., et al (2010). Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. *Breast*, 19(5), 388-395. [More Information]

Lee, C., Lord, S., Stockler, M., Coates, A., GebSKI, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. *European Journal of Cancer*, 46(3), 541-548. [More Information]

Maiorano, E., Regan, M., Viale, G., Mastropasqua, M., Colleoni, M., Castiglione-Gertsch, M., Price, K., Gelber, R., Goldhirsch, A., Coates, A. (2010). Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. *Breast Cancer Research and Treatment*, 121(1), 211-218. [More Information]

Doehner, W., Gathercole, D., Cicoira, M., Krack, A., Coates, A., Camici, P., Anker, S. (2010). Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. *International Journal of Cardiology*, 138(1), 19-24. [More Information]

Lee, C., Stockler, M., Coates, A., GebSKI, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. *British Journal of Cancer*, 102(9), 1341-1347. [More Information]

2009

Rabaglio, M., Sun, Z., Price, K., Castiglione-Gertsch, M., Hawle, H., Thurlimann, B., Mouridsen, H., Campone, N., Forbes, J., Paridaens, R., Coates, A. (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. *Annals of Oncology*, 20(9), 1489-1498. [More Information]

Pagani, O., Gelber, S., Simoncini, E., Castiglione-Gertsch, M.,

Price, K., Gelber, R., Holmberg, S., Crivellari, D., Collins, J., Lindtner, J., Coates, A., et al (2009). Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. *Breast Cancer Research and Treatment*, 116(3), 491-500. [More Information]

Thurlimann, B., Price, K., Gelber, R., Holmberg, S., Crivellari, D., Colleoni, M., Collins, J., Forbes, J., Castiglione-Gertsch, M., Coates, A., et al (2009). Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. *Breast Cancer Research and Treatment*, 113, 137-144. [More Information]

Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thurlimann, B., Paridaens, R., Smith, I., Mauriac, L., Forbes, J., Price, K., Coates, A., et al (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *New England Journal of Medicine*, 361(8), 766-776. [More Information]

Lee, C., Lord, S., Coates, A., Simes, R. (2009). Molecular biomarkers to individualise treatment: assessing the evidence. *Medical Journal of Australia*, 190(11), 631-636. [More Information]

Pagani, O., Price, K., Gelber, R., Castiglione-Gertsch, M., Holmberg, S., Lindtner, J., Thurlimann, B., Collins, J., Fey, M., Coates, A., et al (2009). Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. *Breast Cancer Research and Treatment*, 117(2), 319-324. [More Information]

Gianni, L., Gelber, S., Ravaioli, A., Price, K., Panzini, I., Fantini, M., Castiglione-Gertsch, M., Pagani, O., Simoncini, E., Gelber, R., Coates, A., et al (2009). Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. *European Journal of Cancer*, 45(4), 561-571. [More Information]

Colleoni, M., Sun, Z., Martinelli, G., Basser, R., Coates, A., Gelber, R., Green, M., Peccatori, F., Cinieri, S., Aebi, S., et al (2009). The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. *Annals of Oncology*, 20(8), 1344-1351. [More Information]

Goldhirsch, A., Ingle, J., Gelber, R., Coates, A., Thurlimann, B., Senn, H. (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. *Annals of Oncology*, 20(8), 1319-1329. [More Information]

2008

Wapnir, I., Aebi, S., Geyer, C., Zahrieh, D., Gelber, R., Anderson, S., Robidoux, A., Bernhard, J., Maibach, R., Castiglione-Gertsch, M., Coates, A., et al (2008). A randomized

clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. *Clinical Breast Cancer*, 8(3), 287-292. [More Information]

Clarke, M., Coates, A., Darby, S., Davies, C., Gelber, R., Godwin, J., Goldhirsch, A., Gray, R., Peto, R., Pritchard, K., et al (2008). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. *The Lancet*, 371, 29-40. [More Information]

Rasmussen, B., Regan, M., Lykkesfeldt, A., Dell'Orto, P., Del Curto, B., Henriksen, K., Mastropasqua, M., Price, K., Mery, E., Lacroix-Triki, M., Coates, A., et al (2008). Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. *The Lancet*, 9, 23-28. [More Information]

Gianni, L., Cole, B., Panzini, I., Snyder, R., Holmberg, S., Byrne, M., Crivellari, D., Colleoni, M., Aebi, S., et al, Coates, A. (2008). Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. *Supportive Care in Cancer*, 16(1), 67-74. [More Information]

Viale, G., Regan, M., Maiorano, E., Mastropasqua, M., Golouh, R., Perin, T., Brown, R., Kovacs, A., Pillay, K., Ohlschlegel, C., Coates, A., et al (2008). Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors-International Breast Cancer Study Group. *Journal of Clinical Oncology*, 26(9), 1404-1410. [More Information]

Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. *Patient Education and Counseling*, 72(2), 239-245. [More Information]

Dawes, M., Bartlett, G., Coates, A., Juszczak, E. (2008). Comparing the Effects of White Coat Hypertension and Sustained Hypertension on Mortality in a UK Primary Care Setting. *Annals of Family Medicine*, 6(5), 390-396. [More Information]

Pestalozzi, B., Zahrieh, D., Mallon, E., Gusterson, B., Price, K., Gelber, R., Holmberg, S., Lindtner, J., Snyder, R., Thurlimann, B., Coates, A., et al (2008). Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials. *Journal of Clinical Oncology*, 26(18), 3006-3014. [More Information]

Coates, A. (2008). Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. *Annals of Oncology*, 19, 1090-1096. [More Information]

Gruber, G., Cole, B., Castiglione-Gertsch, M., Holmberg, S., Lindtner, J., Golouh, R., Collins, J., Crivellari, D., Thurlimann, B., Simoncini, E., Coates, A., et al (2008). Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. *Annals of Oncology*, 19, 1393-1401. [More Information]

Viale, G., Rotmensz, N., Maisonneuve, P., Orvieto, E., Maiorano, E., Galimberti, V., Luini, A., Colleoni, M., Goldhirsch, A., Coates, A. (2008). Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series. *Breast Cancer Research and Treatment*, 117(1), 211-214. [More Information]

Crivellari, D., Sun, Z., Coates, A., Price, K., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J., Paridaens, R., Castiglione-Gertsch, M., et al (2008). Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. *Journal of Clinical Oncology*, 26(12), 1972-1979. [More Information]

Ravaioli, A., Monti, F., Regan, M., Maffini, F., Mastropasqua, M., Spataro, V., Castiglione-Gertsch, M., Panzini, I., Gianni, L., Goldhirsch, A., Coates, A., et al (2008). p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. *Annals of Oncology*, 19(4), 660-668. [More Information]

Viale, G., Regan, M., Mastropasqua, M., Maffini, F., Maiorano, E., Colleoni, M., Price, K., Golouh, R., Perin, T., et al, Coates, A. (2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. *Journal of the National Cancer Institute*, 100(3), 207-212. [More Information]

Regan, M., Pagani, O., Walley, B., Torrisi, R., Perez, E., Francis, P., Fleming, G., Price, K., Thurlimann, B., et al, Coates, A. (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? *Annals of Oncology*, 19(7), 1231-1241. [More Information]

Viale, G., Giobbie-Hurder, A., Regan, M., Coates, A., Mastropasqua, M., Dell'Orto, P., Maiorano, E., MacGrogan, G., Braye, S., Ohlschlegel, C., et al (2008). Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. *Journal of Clinical Oncology*, 26(34), 5569-5575. [More Information]

Bernhard, J., Zahrieh, D., Zhang, J., Martinelli, G., Basser, R., HÅ¼rny, C., Forbes, J., Aebi, S., Yeo, W., et al, Coates, A. (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. *British Journal of Cancer*, 98(1), 25-33. [More Information]

Keshaviah, A., Dellapasqua, S., Rotmensz, N., Lindtner, J., Crivellari, D., Collins, J., Colleoni, M., Thuerlimann, B., Mendiola, C., et al, Coates, A. (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. *Annals of Oncology*, 18(4), 701-708. [More Information]

Mouridsen, H., Keshaviah, A., Coates, A., Rabaglio, M., Castiglione-Gertsch, M., Sun, Z., Thurlimann, B., Mauriac, L., Forbes, J., Paridaens, R., et al (2007). Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. *Journal of Clinical Oncology*, 25(36), 5715-5722. [More Information]

Colleoni, M., Gelber, S., Simoncini, E., Pagani, O., Gelber, R., Price, K., Castiglione-Gertsch, M., Coates, A., Goldhirsch, A., et al (2007). Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. *Annals of Oncology*, 18(7), 1177-1184. [More Information]

Coates, A., Keshaviah, A., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J., Paridaens, R., Castiglione-Gertsch, M., Gelber, R., Colleoni, M., et al (2007). Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *Journal of Clinical Oncology*, 25(5), 486-492. [More Information]

Piccart, M., Goldhirsch, A., Wood, W., Pritchard, K., Baselga, J., Reaby, L., Kossler, I., Kyriakides, S., Norton, L., Coates, A., et al (2007). Keeping faith with trial volunteers. *Nature*, 446(7132), 137-138. [More Information]

Mauriac, L., Keshaviah, A., Debled, M., Mouridsen, H., Forbes, J., Thurlimann, B., Paridaens, R., Monnier, A., Lang, I., Coates, A., et al (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. *Annals of Oncology*, 18(5), 859-867. [More Information]

Viale, G., Regan, M., Maiorano, E., Mastropasqua, M., Dell'Orto, P., Rasmussen, B., Raffoul, J., Neven, P., Orosz, Z., Coates, A., et al (2007). Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Women With Early Breast Cancer: Results From the BIG 1-98 Collaborative Groups. *Journal of Clinical Oncology*, 25(25), 3846-3852. [More Information]

Goldhirsch, A., Wood, W., Gelber, R., Coates, A., Thurlimann, B., Senn, H. (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. *Annals of Oncology*, 18(7), 1133-1144. [More Information]

Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007).

Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. *Psycho-Oncology*, 16(1), 48-59. [More Information]

Coombes, R., Kilburn, L., Snowdon, C., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, E., Coates, A., et al (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. *The Lancet*, 369(9561), 559-570. [More Information]

Karlsson, P., Cole, B., Price, K., Coates, A., Castiglione-Gertsch, M., Gusterson, B., Murray, E., Lindtner, J., Collins, J., Holmberg, S., et al (2007). The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. *Journal of Clinical Oncology*, 25(15), 2019-2026. [More Information]

2006

Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., GebSKI, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. *Breast Cancer Research and Treatment*, 100(Supplement 1), S278-S278.

Goldhirsch, A., Coates, A., Gelber, R., Glick, J., Thurlimann, B., Senn, H. (2006). First-select the target: better choice of adjuvant treatments for breast cancer patients. *Annals of Oncology*, 17(12), 1772-1776. [More Information]

Pestalozzi, B., Zahrieh, D., Price, K., Holmberg, S., Lindtner, J., Collins, J., Crivellari, D., Fey, M., Murray, E., Pagani, O., Coates, A., et al (2006). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). *Annals of Oncology*, 17(6), 935-944. [More Information]

Bernhard, J., Zahrieh, D., Castiglione-Gertsch, M., Hurny, C., Gelber, R., Forbes, J., Murray, E., Collins, J., Aebi, S., Coates, A., et al (2006). Impact of Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone on Amenorrhoea, Hot Flashes, and Quality of Life in Premenopausal Patients With Lymph Node-Negative Breast Cancer: Results on the Effect of Age From the International. *Journal of Clinical Oncology*, 25(3), 263-270. [More Information]

Coates, A., Mouridsen, H., Mauriac, L. (2006). Letrozole or tamoxifen in early breast cancer - The authors reply. *New England Journal of Medicine*, 354(14), 1529-1530.

Coates, A., Basser, R., O'Neill, A., Martinelli, G., Green, M., Peccatori, F., Cinieri, S., Gelber, R., Aebi, S., Castiglione-Gertsch, M., et al (2006). Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. *Journal of Clinical Oncology*, 24(3), 370-378. [More Information]

Gianni, L., Panzini, I., Li, S., Gelber, R., Collins, J., Holmberg,

S., Crivellari, D., Castiglione-Gertsch, M., Goldhirsch, A., Coates, A., et al (2006). Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer - Results from International Breast Cancer Study Group Trials. *Cancer*, 106(3), 505-513. [More Information]

Stockler, M., Duric, V., Coates, A. (2006). Patients' preferences: what makes treatments worthwhile? In Martine J. Piccart .. [et al.] (Eds.), *Breast cancer and molecular medicine*, (pp. 925-944). Berlin ; New York: Springer.

Rudenstam, C., Zahrieh, D., Forbes, J., Crivellari, D., Holmberg, S., Rey, P., Dent, D., Campbell, I., Bernhard, J., Coates, A., et al (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. *Journal of Clinical Oncology*, 24(3), 337-344. [More Information]

Regan, M., Viale, G., Mastropasqua, M., Maiorano, E., Golouh, R., Carbone, A., Brown, B., SuurkÃ¼la, M., Langman, G., Coates, A., et al (2006). Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. *Journal of the National Cancer Institute*, 98(21), 1571-1581. [More Information]

Colleoni, M., Gelber, S., Goldhirsch, A., Aebi, S., Castiglione-Gertsch, M., Price, K., Coates, A., Gelber, R., et al (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. *Journal of Clinical Oncology*, 24(9), 1332-1341. [More Information]

Yu, X., Oâ€™Connell, D., Gibberd, R., Coates, A., Armstrong, B. (2006). Trends in survival and excess risk of death after diagnosis of cancer in 1980-1996 in New South Wales, Australia. *International Journal of Cancer*, 119(4), 894-900. [More Information]

2005

Thurlimann, B., Keshaviah, A., Coates, A., Mouridsen, H., Mauriac, L., Forbes, J., Paridaens, R., Castiglione-Gertsch, M., Gelber, R., Rabaglio, M., et al (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *New England Journal of Medicine*, 353(26), 2747-2757. [More Information]

Stewart, B., Coates, A. (2005). Cancer prevention: a global perspective. *Journal of Clinical Oncology*, 23(2), 392-403. [More Information]

Duric, V., Stockler, M., Butow, P., Sharpe, L., Heritier, S., Beith, J., Boyle, F., Wilcken, N., Coates, A., Simes, R. (2005). Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). *Journal of Clinical Oncology*, 23(16S), 546S-546S.

Coates, A., Senn, H., Cuzick, J., Davidson, N., Goss, P., Ingle, J., Jassem, J., Possinger, K., Rutgers, E., Wallgren, A., et al (2005). Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. *Annals of Oncology*, 16(10), 1569-1583.

Duric, V., Stockler, M., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A., Simes, R. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? *Annals of Oncology*, 16(11), 1786-1794. [More Information]

Duric, V., Fallowfield, L., Saunders, C., Houghton, J., Coates, A., Stockler, M. (2005). Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? *British Journal of Cancer*, 93(12), 1319-1323. [More Information]

Coates, A., Gruber, G., Bonetti, M., Nasi, M., Price, A., Castiglione-Gertsch, M., Rudenstam, C., Holmberg, S., Lindtner, J., Golouh, R., et al (2005). Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: Long-term observations from international breast ca. *Journal of Clinical Oncology*, 23(28), 7089-7097. [More Information]

Colleoni, M., Li, S., Gelber, R., Price, K., Coates, A., Castiglione-Gertsch, M., Goldhirsch, A. (2005). Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. *The Lancet*, 366(9491), 1108-1110. [More Information]

Colleoni, M., Zahrieh, D., Gelber, R., Holmberg, S., Mattsson, J., Rudenstam, C., Lindtner, J., Erzen, D., Snyder, R., Coates, A., et al (2005). Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience. *Journal of Clinical Oncology*, 23(7), 1390-1400. [More Information]

Colleoni, M., Li, S., Gelber, R., Coates, A., Castiglione-Gertsch, M., Price, K., Lindtner, J., Rudenstam, C., Crivellari, D., Collins, J., et al (2005). Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. *Annals of Oncology*, 16(5), 716-725. [More Information]

Goldhirsch, A., Gelber, R., Coates, A. (2005). What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer? *Nature Clinical Practice Oncology*, 2(9), 440-441.

2004

Coombes, R., Hall, E., Gibson, L., Paridaens, R., Jassem, J., Delozier, T., Jones, S., Alvarez, I., Bertelli, G., Ortmann, O., Coates, A., et al (2004). A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer. *New England Journal of Medicine*, 350(11), 1081-1092. [More Information]

Berclaz, G., Li, S., Price, K., Coates, A., Castiglione-Gertsch, M., Rudenstam, C., Holmberg, S., Lindtner, J., Erzen, D., Collins, J., et al (2004). Body Mass Index As A Prognostic Feature In Operable Breast Cancer: The International Breast Cancer Study Group Experience. *Annals of Oncology*, 15(6), 875-884. [More Information]

<http://dx.doi.org/10.1093/annonc/mdh222>>[More Information]

Duric, V., Stockler, M., Butow, P., Sharpe, L., Beith, J., Sullivan, A., Boyle, F., Dhillon, H., Coates, A., Simes, R. (2004). Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). *Journal of Clinical Oncology*, 22(14S), 73S-73S.

Barratt, A., Coates, A. (2004). Screening decreases prostate cancer death: first analysis of the 1988 Quebec Prospective Randomized Controlled Trial. *Medical Journal of Australia*, 181(4), 213-214.

2003

Castiglione-Gertsch, M., O'Neill, A., Price, K., Goldhirsch, A., Coates, A., Colleoni, M., Nasi, M., Bonetti, M., Gelber, R. (2003). Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. *Journal of the National Cancer Institute*, 95(24), 1833-1846. [More Information]

Crivellari, D., Price, K., Gelber, R., Castiglione-Gertsch, M., Rudenstam, C., Lindtner, J., Fey, M., Senn, H., Coates, A., Collins, J., et al (2003). Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. *Journal of Clinical Oncology*, 21(24), 4517-4523. [More Information]

Stockler, M., Wilcken, N., Coates, A. (2003). Chemotherapy for advanced breast cancer- how long should it continue? *Breast Cancer Research and Treatment*, 81(Suppl 1), S49-S52.

Senn, H., Thurlimann, B., Goldhirsch, A., Wood, W., Gelber, R., Coates, A. (2003). Comments on the St. Gallen Consensus 2003 on the primary therapy of early breast cancer. *Breast*, 12, 569-582. [More Information]

Spataro, V., Litman, H., Viale, G., Maffini, F., Masullo, M., Golouh, R., Martinez-Tello, F., Grigolato, P., Castiglione-Gertsch, M., Price, K., Coates, A., et al (2003). Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status. *Cancer*, 97(7), 1591-1600. [More Information]

Trihia, H., Murray, S., Price, A., Gelber, R., Golouh, R., Goldhirsch, A., Coates, A., Collins, J., Castiglione-Gertsch, M., Gusterson, B. (2003). Ki-67 expression in breast carcinoma. *Cancer*, 97(5), 1321-1331. [More Information]

Goldhirsch, A., Wood, W., Gelber, R., Coates, A., Thurlimann, B., Senn, H. (2003). Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. *Journal of Clinical Oncology*, 21(17), 3357-3365. [More Information]

Hornbuckle, J., Culjak, G., Jarvis, E., GebSKI, V., Coates, A., Mann, G., Kefford, R. (2003). Patterns of metastases in familial and non-familial melanoma. *Melanoma Research*, 13(1), 105-

109. [More Information]

Wallgren, A., Bonetti, M., Gelber, R., Goldhirsch, A., Castiglione-Gertsch, M., Holmberg, S., Lindtner, J., Thurlimann, B., Fey, M., Coates, A., et al (2003). Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. *Journal of Clinical Oncology*, 21(7), 1205-1213. [More Information]

Gelber, R., Bonetti, M., Castiglione-Gertsch, M., Coates, A., Goldhirsch, A. (2003). Tailoring adjuvant treatment for the individual breast cancer patient. *Breast*, 12(6), 558-568. [More Information]

2002

Coates, A., Thompson, J., McMullen, A., Simes, R., McCarthy, W., Hersey, P., Sillar, R., McLeod, R., Gill, P., Coventry, B., Dhillon, H. (2002). Adjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial. *Journal of Clinical Oncology*, 20(20), 4181-4189.

Colleoni, M., Litman, H., Castiglione-Gertsch, M., Sauerbrei, W., Gelber, R., Bonetti, M., Coates, A., Schumacher, M., Bastert, G., Rudenstam, C., et al (2002). Duration of Adjuvant Chemotherapy for Breast Cancer: A Joint Analysis of Two Randomised Trials Investigating Three Versus Six Courses of CMF. *British Journal of Cancer*, 86, 1705-1714.

Castiglione-Gertsch, M., Price, K., Goldhirsch, A., Coates, A., Colleoni, M., Nasi, M., Bernhard, J., Zahrieh, D., Bonetti, M., Gelber, R. (2002). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial. *Journal of the National Cancer Institute*, 94(14), 1054-1065.

Cuzick, J., Forbes, J., Edwards, R., Baum, M., Cawthorn, S., Coates, A., Hamed, H., Howell, A., Powels, T., Dhillon, H., GebSKI, V., Simes, R. (2002). First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. *The Lancet*, 360(9336), 817-824. [More Information]

2001

Goldhirsch, A., Gelber, R., Yothers, G., Gray, R., Green, S., Bryant, J., Gelber, S., Castiglione-Gertsch, M., Coates, A. (2001). Adjuvant therapy for very young women with breast cancer: need for tailored treatments. *Journal of the National Cancer Institute*, 30, 44-51.

Coates, A., Bernhard, J., Sullivan, M., Hurny, C., Rudenstam, C. (2001). Clinical relevance of single item quality of life indicators in cancer clinical trials. *British Journal of Cancer*, 84(9), 1156-1165. [More Information]

Coates, A., Gelber, S., Goldhirsch, A., Castiglione-Gertsch, M., Marini, G., Lindtner, J., Edelmann, D., Gudgeon, A., Harvey, V., Gelber, R. (2001). Effect of Pregnancy on Overall Survival after the diagnosis of early-stage breast cancer. *Journal of Clinical Oncology*, 19, 1671-1675.

Coates, A., Bonetti, M., Gelber, R., Hirsch, D., Castiglione-Gertsch, M. (2001). Features that predict responsiveness to chemotherapy and endocrine therapies. *Breast*, 10 (Supplement 3), 147-157.

Coates, A., Colleoni, M., Gelber, R., Gelber, S., Castiglione-

Gertsch, M., Hirsch, D. (2001). How to improve timing and duration of adjuvant chemotherapy. *Breast*, 10 (Supplement 3), 101-105.

Coates, A., Bonetti, M., Gelber, R., Hirsch, D. (2001). Innovative strategies of adjuvant treatments. *Breast*, 10, 147-157.

Coates, A., Goldhirsch, A., Glick, J., Gelber, R., Senn, H. (2001). Meeting Highlights: international consensus panel on the treatment of primary breast cancer. *Journal of Clinical Oncology*, 19, 3817-3827.

Simes, R., Coates, A. (2001). Patient preferences for adjuvant chemotherapy of early breast cancer: How much benefit is needed? *Journal of the National Cancer Institute*, 30, 146-152.

[More Information]

Coates, A., Cole, B., Gelber, R., Gelber, S., Hirsch, D. (2001). Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. *The Lancet*, 358, 277-286. [More Information]

Butow, P., Dunn, S., Coates, A., Brown, J. (2001). Psychosocial predictors of outcome IV: patients with early-stage breast cancer. *Breast*, 10, 182-189.

Coates, A., Hurny, C., Peterson, H., Bernhard, J., Castiglione-Gertsch, M., Gelber, R., Goldhirsch, A. (2001). Quality of life scores predict outcome in metastatic but not in early breast cancer. *Breast*, 10 (Supplement 3), 164-170.

Coates, A., Thurlimann, B., Price, A., Castiglione-Gertsch, M., Goldhirsch, A., Gelber, R., Forbes, J., Holmberg, S., Veronesi, A., Bernhard, J. (2001). Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. *Breast*, 10 (Supplement 3), 130-138.

Coates, A., Kitchen, P., Smith, H., Henderson, M., Goldhirsch, A., Castiglione-Gertsch, M., Gusterson, B., Brown, R., Gelber, R., Collins, J. (2001). Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy. *ANZ Journal of Surgery*, 71, 27-31.